SRRK — Scholar Rock Holding Corp
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1727196 ·
Last close
$45.08
Market Cap
$5.50B
52W High
$61.76
52W Low
$36.78
ADV30
1,726,088
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 570,000 | 562,000 | -106,061,000 | -107,239,000 | 445,972,000 | 366,269,000 | 277,296,000 |
| Jun 2026 | 0 | — | -108,901,000 | -109,896,000 | 523,543,000 | 437,091,000 | 269,759,000 |
| Mar 2026 | 0 | — | -102,016,000 | -105,510,000 | 535,254,000 | 430,543,000 | 259,241,000 |
| Dec 2025 | 0 | — | -91,896,000 | -90,965,000 | 404,272,000 | 323,527,000 | 158,784,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-309,711,000
Investing CF
$36,077,000
Financing CF
$353,318,000
CapEx
$-202,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.36
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,623,299,000
Inventory
$773,000
Receivables
$2,368,000
ST Investments
$47,330,000
EBIT TTM
$-399,622,000
Pretax Income TTM
$-413,610,000
Interest Exp TTM
$13,988,000
Analysts
16
Yahoo Snapshot (yfinance, live)
Total Revenue
$570,000
EBITDA
$-407,559,008
Free Cash Flow
$-168,629,744
Enterprise Value
$5,060,597,248
Total Cash
$413,599,008
Total Debt
$202,992,992
Shares Out
122,004,478
Trailing EPS
$-3.23
Book Value
$1.38
ROE
-200.0%
ROA
-59.6%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -384,645,000 | -377,939,000 | 404,272,000 | 158,784,000 | 245,488,000 | -300,035,000 |
| Dec 2024 | 0 | -252,054,000 | -246,294,000 | 474,922,000 | 106,288,000 | 368,634,000 | -200,949,000 |
| Dec 2023 | 0 | -171,295,000 | -165,789,000 | 311,035,000 | 85,817,000 | 225,218,000 | -145,226,000 |
| Dec 2022 | 33,193,000 | -134,370,000 | -134,502,000 | 358,168,000 | 97,933,000 | 260,235,000 | -132,694,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-408,591,000
OpCashFlow TTM
—
Assets (Latest)
$523,543,000
Forward EPS
$-2.45
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $55.00 · spot: $48.00 · call volume: 179 · put volume: 1,638
Expected Move to 2027-01-15:
±$8.06
(16.79%) —
implied range
$39.94 –
$56.06
· ATM straddle on $50.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KOD | Kodiak Sciences Inc. | $6.33B | $96.80 | — |
| ADPT | Adaptive Biotechnologies Corp | $4.61B | $28.49 | — |
| IBRX | ImmunityBio, Inc. | $6.66B | $6.26 | — |
| IMVT | Immunovant, Inc. | $6.87B | $33.21 | — |
| CGON | CG Oncology, Inc. | $7.00B | $78.94 | — |
News headlines (Yahoo Finance, 1h cache)
Scholar Rock to Present at Upcoming Investor Conferences
2026-11-17 13:00 · Yahoo
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-13 21:15 · Yahoo
Scholar Rock (SRRK) Q3 2026 Earnings Call Transcript
2026-11-10 19:31 · Yahoo
What Scholar Rock (SRRK) Said on Its Q3 Earnings Call
2026-11-10 18:15 · Yahoo
Scholar Rock Holding Corporation (SRRK) Reports Q3 Loss, Beats Revenue Estimates
2026-11-10 12:05 · Yahoo
Scholar Rock Reports Third Quarter 2026 Financial Results and Recent Business Highlights
2026-11-10 12:00 · Yahoo
Scholar Rock (SRRK) Stock Could Trade At A Premium On Balance Sheet Hopes
2026-10-30 09:13 · Yahoo
EMA Resubmission for Apitegromab Might Change The Case For Investing In Scholar Rock Holding (SRRK)
2026-10-16 01:20 · Yahoo
Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)
2026-10-08 12:00 · Yahoo
3 drug targets pharma is betting on next
2026-10-02 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.